Tianfeng Xu

1.8k citations

30 papers · 1.3k indexed · 2 hit papers · h-index 19

Molecular Biology top 10%
Oncology top 5%
Hematology top 5%
Organic Chemistry top 10%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Shaomeng Wang Jeanne A. Stuckey Krishnapriya Chinnaswamy Mi Wang Lijie Zhao Xin Han Weiguo Xiang Chong Qin
Topics: Protein Degradation and Inhibitors (18 papers)Ubiquitin and proteasome pathways (12 papers)Peptidase Inhibition and Analysis (11 papers)
Cited by: Hematology Oncology Molecular Biology
Journals: Angewandte Chemie International Edition Nature Communications The FASEB Journal
Partner nations: China United States Singapore

In The Last Decade

Tianfeng Xu

28 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

2019 303 citations Ester Fernández‐Salas, Mi Wang et al. Journal of Medicinal Chemistry profile →
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

2022 143 citations Jing Gao, Bo Hou et al. Nature Communications profile →

Peers

Countries citing papers authored by Tianfeng Xu

Since Specialization

Citations

This map shows the geographic impact of Tianfeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tianfeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tianfeng Xu more than expected).

Fields of papers citing papers by Tianfeng Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tianfeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tianfeng Xu. The network helps show where Tianfeng Xu may publish in the future.

Co-authorship network of co-authors of Tianfeng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Tianfeng Xu. A scholar is included among the top collaborators of Tianfeng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tianfeng Xu. Tianfeng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	M2c Macrophages Mediate YAP1 to Promote Vascularized Bone Regeneration in Distraction Osteogenesis 2025 ·The FASEB Journal ·Haifeng Liu,Kai Liu,(unknown),(unknown),(unknown),(unknown),Tianfeng Xu,Nuo Zhou,(unknown),Xuanping Huang	1
2	An overview of PROTACs targeting KRAS and SOS1 as antitumor agents 2025 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Qiaolin Wu,H. Surya Prakash Rao,Tianfeng Xu,Chuan Zhou	0
3	Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor 2024 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Chuan Zhou,Huajie Li,Mingyue Zheng,Sulin Zhang,Tianfeng Xu	3
4	Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS^G12D 2024 ·Journal of Medicinal Chemistry ·Chuan Zhou,Zisheng Fan,(unknown),Zhiming Ge,(unknown),Rongrong Cui,Yupeng Li,(unknown),(unknown),(unknown),(unknown),(unknown),Mingyue Zheng,Sulin Zhang,Tianfeng Xu	21
5	An updated patent review of SOS1 inhibitors (2022–present) 2024 ·Expert Opinion on Therapeutic Patents ·(unknown),Chuan Zhou,(unknown),(unknown),(unknown),Tianfeng Xu,Mingyue Zheng,Sulin Zhang	0
6	Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders 2024 ·ACS Medicinal Chemistry Letters ·Huajie Li,Zhiming Ge,Kexin Lin,Wei He,(unknown),Mingyue Zheng,Sulin Zhang,Tianfeng Xu	7
7	Stimuli-activatable PROTACs for precise protein degradation and cancer therapy 2023 ·Science Bulletin ·Jing Gao,Lei Yang,(unknown),Feng Zhou,(unknown),Bo Peng,Tianfeng Xu,Xiaohua Chen,Xiaobao Yang,Chunquan Sheng,Yu Rao,Kanyi Pu,Jian Jin,Zhiai Xu,Haijun Yu	56
8	Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity 2023 ·Journal of Medicinal Chemistry ·Zhixiang Chen,Biao Hu,Rohan Kalyan Rej,(unknown),(unknown),Mingliang Wang,Tianfeng Xu,Jianfeng Lü,Hoda Metwally,Yu Wang,Donna McEachern,Longchuan Bai,Christina L. Gersch,(unknown),Wenjing Zhang,Qiuxia Li,Bo Wen,Duxin Sun,James M. Rae,Shaomeng Wang	25
9	Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors 2023 ·ACS Medicinal Chemistry Letters ·Meiying Liu,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Yupeng Li,(unknown),Kaixian Chen,Mingyue Zheng,Sulin Zhang,Tianfeng Xu	19
10	Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers 2023 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Chuan Zhou,Zisheng Fan,Rongrong Cui,Yupeng Li,Rui Li,(unknown),Huajie Li,Zhiming Ge,Xiaojia Cai,Bing Jiang,Dan Wang,Mingyue Zheng,Tianfeng Xu,Sulin Zhang	28
11	Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors 2022 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Zhiwen Chen,Meiying Liu,(unknown),Chaoyi Liu,Rui Li,(unknown),Mingyue Zheng,Zhengchao Tu,Zhang Zhang,Tianfeng Xu	10
12	Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapybreakdown → 2022 ·Nature Communications ·Jing Gao,Bo Hou,Qiwen Zhu,Lei Yang,Xingyu Jiang,Zhifeng Zou,Xutong Li,Tianfeng Xu,Mingyue Zheng,Yi‐Hung Chen,Zhiai Xu,(unknown),Haijun Yu	143
13	Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations 2022 ·Journal of Medicinal Chemistry ·Chuan Zhou,Zisheng Fan,(unknown),Yupeng Li,Rongrong Cui,Chaoyi Liu,(unknown),Xingxing Diao,Hualiang Jiang,Mingyue Zheng,Sulin Zhang,Tianfeng Xu	61
14	Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein–Protein Interaction 2019 ·Journal of Medicinal Chemistry ·Angelo Aguilar,Ke Zheng,Tianfeng Xu,Shilin Xu,Liyue Huang,Ester Fernández‐Salas,Liu Liu,Denzil Bernard,(unknown),(unknown),Donna McEachern,Jeanne A. Stuckey,Krishnapriya Chinnaswamy,James Delproposto,Jeff W. Kampf,Shaomeng Wang	27
15	Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction 2017 ·Angewandte Chemie International Edition ·Shilin Xu,Angelo Aguilar,Tianfeng Xu,Ke Zheng,Liyue Huang,Jeanne A. Stuckey,Krishnapriya Chinnaswamy,Denzil Bernard,Ester Fernández‐Salas,Liu Liu,Mi Wang,Donna McEachern,Sally Przybranowski,(unknown),Shaomeng Wang	51
16	Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction 2017 ·Angewandte Chemie ·Shilin Xu,Angelo Aguilar,Tianfeng Xu,Ke Zheng,Liyue Huang,Jeanne A. Stuckey,Krishnapriya Chinnaswamy,Denzil Bernard,Ester Fernández‐Salas,Liu Liu,Mi Wang,Donna McEachern,Sally Przybranowski,(unknown),Shaomeng Wang	2
17	A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties 2016 ·European Journal of Medicinal Chemistry ·Lei Yu,Minhao Huang,Tianfeng Xu,Linjiang Tong,Xiao-E Yan,Zhang Zhang,Yong Xu,Cai‐Hong Yun,Hua Xie,Ke Ding,Xiaoyun Lu	36
18	Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine⁷⁹⁰ to Methionine⁷⁹⁰ (T790M) Mutants 2013 ·Angewandte Chemie International Edition ·Tianfeng Xu,Lianwen Zhang,Shilin Xu,(unknown),Jinfeng Luo,Fang Ding,Xiaoyun Lu,Yingxue Liu,Zhengchao Tu,Shiliang Li,Duanqing Pei,Qian Cai,Honglin Li,Xiaomei Ren,Shaomeng Wang,Ke Ding	28
19	Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine⁷⁹⁰ to Methionine⁷⁹⁰ (T790M) Mutants 2013 ·Angewandte Chemie ·Tianfeng Xu,Lianwen Zhang,Shilin Xu,(unknown),Jinfeng Luo,Fang Ding,Xiaoyun Lu,Yingxue Liu,Zhengchao Tu,Shiliang Li,Duanqing Pei,Qian Cai,Honglin Li,Xiaomei Ren,Shaomeng Wang,Ke Ding	1
20	Structure-activity relationships of 1'-acetoxychavicol acetate homologues as new nuclear export signal inhibitors. 2007 ·PubMed ·Yonghong Liu,N. MURAKAMI,(unknown),Tianfeng Xu	5

About Tianfeng Xu

Tianfeng Xu is a scholar working on Hematology, Oncology and Molecular Biology, having authored 30 papers that have together received 1.3k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (18 papers), Ubiquitin and proteasome pathways (12 papers) and Peptidase Inhibition and Analysis (11 papers). The work is most often cited by research in Hematology (276 citations), Oncology (536 citations) and Molecular Biology (1.1k citations). Tianfeng Xu has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Shaomeng Wang, Jeanne A. Stuckey, Krishnapriya Chinnaswamy, Mi Wang, Lijie Zhao, Xin Han, Weiguo Xiang, Chong Qin, Chao‐Yie Yang and Ke Ding. Their work appears in journals such as Angewandte Chemie International Edition, Nature Communications and The FASEB Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact